BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16547768)

  • 1. Effects of siRNAs in combination with Gleevec on K-562 cell proliferation and Bcr-Abl expression.
    Baker BE; Kestler DP; Ichiki AT
    J Biomed Sci; 2006 Jul; 13(4):499-507. PubMed ID: 16547768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of bcr-abl and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes.
    Ohba H; Zhelev Z; Bakalova R; Ewis A; Omori T; Ishikawa M; Shinohara Y; Baba Y
    Cancer; 2004 Sep; 101(6):1390-403. PubMed ID: 15368327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
    Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y
    FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells.
    Elmaagacli AH; Koldehoff M; Peceny R; Klein-Hitpass L; Ottinger H; Beelen DW; Opalka B
    Haematologica; 2005 Mar; 90(3):326-34. PubMed ID: 15749664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibitory effect of RNA interference on chronic myeloid leukemia bcr/abl oncogene expression].
    Ma XX; Wang C; Wei J; Qin YW; Yan SK; Gao YR; Cai Q
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):359-62. PubMed ID: 16185484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Construction of eukaryotic expression vector of siRNA specific to bcr/abl fusion gene].
    Xi YM; Liu T; Meng WT; Wang YH; Gu L; Lu XX; Gong YP
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Jul; 36(4):460-3. PubMed ID: 16078560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
    Withey JM; Harvey AJ; Crompton MR
    Leuk Res; 2006 May; 30(5):553-60. PubMed ID: 16260034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment.
    Mendonça LS; Firmino F; Moreira JN; Pedroso de Lima MC; Simões S
    Bioconjug Chem; 2010 Jan; 21(1):157-68. PubMed ID: 20000596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient silencing of bcr/abl oncogene by single- and double-stranded siRNAs targeted against b2a2 transcripts.
    Rapozzi V; Xodo LE
    Biochemistry; 2004 Dec; 43(51):16134-41. PubMed ID: 15610007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibition of invasive and chemotactic abilities of SKOV3 cells by human epithelial growth receptor-2 small interfering RNA].
    Zhang SL; Lu YM; Meng LR; Zhao YY
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):48-53. PubMed ID: 17331422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
    Arthanari Y; Pluen A; Rajendran R; Aojula H; Demonacos C
    J Control Release; 2010 Aug; 145(3):272-80. PubMed ID: 20403398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A; Banerjee D; Chandra S; Banerjee S
    J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi).
    Wilda M; Fuchs U; Wössmann W; Borkhardt A
    Oncogene; 2002 Aug; 21(37):5716-24. PubMed ID: 12173041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy.
    Scherr M; Battmer K; Schultheis B; Ganser A; Eder M
    Gene Ther; 2005 Jan; 12(1):12-21. PubMed ID: 15602589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Construction of a gastric cancer related gene GCRG213-specific siRNA expression vector and its effect on gastric cancer cells in vitro].
    Gao LL; Wu BY; Wang MW; Zhan DW; Zhang L; You WD; Wang WH
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):84-8. PubMed ID: 17645837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK.
    Brózik A; Casey NP; Hegedus C; Bors A; Kozma A; Andrikovics H; Geiszt M; Német K; Magócsi M
    Ann N Y Acad Sci; 2006 Dec; 1090():344-54. PubMed ID: 17384279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA interference--about the reality to be exploited in cancer therapy.
    Bakalova R
    Methods Find Exp Clin Pharmacol; 2007; 29(6):417-21. PubMed ID: 17922071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Specific inhibition of HER-2 expression in ovarian carcinoma cells by siRNA targeting HER-2].
    Lu YM; Zhang SL; Meng LR; Zhao YY
    Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(9):619-23. PubMed ID: 16681908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells.
    Withey JM; Marley SB; Kaeda J; Harvey AJ; Crompton MR; Gordon MY
    Br J Haematol; 2005 May; 129(3):377-80. PubMed ID: 15842662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.